QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NYSE:BMY

Bristol-Myers Squibb (BMY) Competitors

$65.98
+0.32 (+0.49%)
(As of 06/5/2023 ET)
Compare
Today's Range
$65.69
$66.46
50-Day Range
$63.70
$70.74
52-Week Range
$63.07
$81.43
Volume
6.86 million shs
Average Volume
8.12 million shs
Market Capitalization
$138.61 billion
P/E Ratio
19.24
Dividend Yield
3.46%
Price Target
$79.43

BMY vs. ZTS, PFE, ABBV, MRK, JNJ, LLY, SNY, ABT, VRTX, and REGN

Should you be buying Bristol-Myers Squibb stock or one of its competitors? The main competitors of Bristol-Myers Squibb include Zoetis (ZTS), Pfizer (PFE), AbbVie (ABBV), Merck & Co., Inc. (MRK), Johnson & Johnson (JNJ), Eli Lilly and (LLY), Sanofi (SNY), Abbott Laboratories (ABT), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN). These companies are all part of the "pharmaceutical preparations" industry.

Bristol-Myers Squibb vs.

Zoetis (NYSE:ZTS) and Bristol-Myers Squibb (NYSE:BMY) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, community ranking, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Bristol-Myers Squibb had 14 more articles in the media than Zoetis. MarketBeat recorded 20 mentions for Bristol-Myers Squibb and 6 mentions for Zoetis. Zoetis' average media sentiment score of 0.88 beat Bristol-Myers Squibb's score of 0.08 indicating that Zoetis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zoetis
3 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Bristol-Myers Squibb
3 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Bristol-Myers Squibb received 190 more outperform votes than Zoetis when rated by MarketBeat users. However, 77.57% of users gave Zoetis an outperform vote while only 67.86% of users gave Bristol-Myers Squibb an outperform vote.

CompanyUnderperformOutperform
ZoetisOutperform Votes
868
77.57%
Underperform Votes
251
22.43%
Bristol-Myers SquibbOutperform Votes
1058
67.86%
Underperform Votes
501
32.14%

Zoetis pays an annual dividend of $1.50 per share and has a dividend yield of 0.9%. Bristol-Myers Squibb pays an annual dividend of $2.28 per share and has a dividend yield of 3.5%. Zoetis pays out 33.9% of its earnings in the form of a dividend. Bristol-Myers Squibb pays out 66.5% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has increased its dividend for 9 consecutive years and Bristol-Myers Squibb has increased its dividend for 16 consecutive years. Bristol-Myers Squibb is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Zoetis has a net margin of 25.59% compared to Bristol-Myers Squibb's net margin of 15.95%. Bristol-Myers Squibb's return on equity of 51.75% beat Zoetis' return on equity.

Company Net Margins Return on Equity Return on Assets
Zoetis 25.59% 50.26% 16.24%
Bristol-Myers Squibb 15.95% 51.75% 17.05%

Zoetis presently has a consensus target price of $221.14, suggesting a potential upside of 29.14%. Bristol-Myers Squibb has a consensus target price of $78.62, suggesting a potential upside of 18.54%. Given Zoetis' stronger consensus rating and higher possible upside, equities research analysts clearly believe Zoetis is more favorable than Bristol-Myers Squibb.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zoetis
0 Sell rating(s)
0 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
3.00
Bristol-Myers Squibb
1 Sell rating(s)
6 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.38

90.2% of Zoetis shares are held by institutional investors. Comparatively, 75.5% of Bristol-Myers Squibb shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 0.1% of Bristol-Myers Squibb shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Bristol-Myers Squibb has higher revenue and earnings than Zoetis. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$8.08 billion9.78$2.11 billion$4.4338.60
Bristol-Myers Squibb$46.16 billion3.00$6.33 billion$3.4319.23

Zoetis has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Bristol-Myers Squibb has a beta of 0.44, indicating that its stock price is 56% less volatile than the S&P 500.

Summary

Zoetis beats Bristol-Myers Squibb on 13 of the 21 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BMY vs. The Competition

MetricBristol-Myers SquibbPharmaceutical IndustryMedical SectorNYSE Exchange
Market Cap$138.57B$5.74B$4.48B$14.67B
Dividend Yield3.47%2.61%6.01%3.98%
P/E Ratio19.235.13101.4619.03
Price / Sales3.00323.133,443.988.92
Price / Cash5.2120.1522.1215.61
Price / Book4.514.784.666.97
Net Income$6.33B$187.16M$116.24M$895.46M
7 Day Performance3.35%4.01%3.31%2.81%
1 Month Performance-3.20%2.04%2.93%2.33%
1 Year Performance-12.25%19.10%13.23%-8.18%

Bristol-Myers Squibb Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ZTS
Zoetis
2.861 of 5 stars
$161.00
-2.3%
$221.14
+37.4%
+1.7%$74.40B$8.09B36.3413,800
PFE
Pfizer
3.0464 of 5 stars
$37.02
-1.5%
$47.33
+27.9%
-27.9%$208.99B$100.33B7.2983,000
ABBV
AbbVie
2.7176 of 5 stars
$136.48
-0.8%
$163.40
+19.7%
-7.0%$240.79B$58.05B32.2650,000
MRK
Merck & Co., Inc.
2.8966 of 5 stars
$109.18
-1.7%
$120.75
+10.6%
+25.1%$277.04B$59.28B21.3269,000
JNJ
Johnson & Johnson
2.4867 of 5 stars
$154.36
+0.0%
$173.00
+12.1%
-11.0%$401.14B$94.94B32.29155,800
LLY
Eli Lilly and
2.8489 of 5 stars
$427.51
+0.4%
$425.05
-0.6%
+46.6%$405.82B$28.54B67.9739,000Analyst Upgrade
Insider Selling
SNY
Sanofi
2.3998 of 5 stars
$50.45
-3.9%
$94.50
+87.3%
-4.7%$127.23B$45.31B18.0891,573Dividend Cut
Gap Down
ABT
Abbott Laboratories
3.0156 of 5 stars
$101.72
-1.1%
$121.26
+19.2%
-10.6%$176.89B$43.65B30.92115,000
VRTX
Vertex Pharmaceuticals
2.4317 of 5 stars
$325.30
-1.4%
$352.59
+8.4%
+23.9%$83.78B$8.93B25.904,800
REGN
Regeneron Pharmaceuticals
2.4896 of 5 stars
$728.60
+0.5%
$850.21
+16.7%
+17.4%$79.66B$12.17B19.8011,851Insider Selling

Related Companies and Tools

This page (NYSE:BMY) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -